News and Trends 23 Nov 2016 These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’ GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […] November 23, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024? Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Sanofi quietly leaves Bladder Cancer Patients in the lurch Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 One Antibody to Neutralize 98% of All HIV Strains: Closer to a Cure? A new hope for HIV: a single antibody that can target nearly all viral strains at once. What does it mean for the search of a global cure? Last week, a research article in Cell Immunity reported a detailed study of an antibody that could neutralize 98% of HIV strains. The N6 antibody can also […] November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 Celyad’s Autologous CAR-T Therapy enters Phase Ib Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […] November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 “We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease” Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […] November 21, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2016 Looking for outperforming cell lines ? CHOvolution is an all-in-one kit for GMP Bioproduction For any drug developer or service provider, cell line development is one of the most challenging phases, especially when subsequent GMP compliance is required. The need to secure good cell lines can, therefore, make all the difference in getting any biological to the market. The Swiss company Celonic has produced CHOvolution™, a cell line kit that allows you to […] November 19, 2016 - 4 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2016 Teaching Bacteria to make Living, Evolving Typography Ori Elisar is an Israeli artist working on Biodesign. His globally-acclaimed project uses bacteria to create living typography that changes over time to represent the evolution of the Hebrew language. The Living Language project uses Paenibacillus vortex bacteria to create living typography. To represent the evolution of the Hebrew language, the artist makes bacteria grow […] November 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 14 More Stories: CRISPR enters Humans, Biocartis makes a Splash Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Biocartis had a big week. The molecular diagnostics company raised €32.7M in an equity […] November 18, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 These Spider Silk Sneakers from Adidas Are Biodegradable Adidas just unveiled a biodegradable sneaker prototype made with a spider silk biomaterial manufactured by the German biotech AMSilk. Is this the beginning of a new era for sustainable biomaterials? AMSilk, located near Munich, is the world’s first biotech supplying synthetic silk biopolymers for textiles, cosmetics and medical devices. The company’s 100% biodegradable and vegan […] November 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 Microfluidics and Biosensors to tackle Antibiotic Resistance A little biosensor can analyze if there are antibiotics in your blood in 10 minutes. Developed by researchers from the University of Freiburg, the system could be used to develop a personalized course of antibiotics, but also to test food and water. The objective? Slow down the rise of multi-resistant bacteria. The World Antibiotic Awareness […] November 18, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 Can Oncolytic Viruses be the key to Treat Resistant Tumors? This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […] November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email